🇺🇸 FDA
Pipeline program

Brodalumab 70 mg, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP, without the active substance., Kyntheum 210 mg solution for injection in pre-filled syringe

LP0160-1329

Approved small_molecule active

Quick answer

Brodalumab 70 mg, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP, without the active substance., Kyntheum 210 mg solution for injection in pre-filled syringe for Moderate-to-severe plaque psoriasis and a body weight ≥120 kg. is a Approved program (small_molecule) at LEO Pharma A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
LEO Pharma A/S
Indication
Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials